logo
  

Moderna Plans To Establish MRNA Manufacturing And Research Center In U.K.

Moderna Inc. (MRNA) said Tuesday that it plans to establish an mRNA Innovation and Technology Center in the UK.

The company expects its state-of-the-art manufacturing facility to produce mRNA vaccines, including vaccines against COVID-19, seasonal influenza, respiratory syncytial virus (RSV), and potential other vaccines, with the collaboration of the United Kingdom government.

The company plans to expand its presence in the UK through investments in R&D to complement its substantial global R&D activities.

Moderna is collaborating with the National Institute for Health Research on a Phase 3 study investigating Moderna's bivalent Omicron-containing booster candidate (mRNA-1273.214) in the UK.

Separately, the UK government purchased 60 million doses of Moderna's COVID-19 vaccine, which may include authorized booster vaccine candidates for delivery in 2022 and 2023.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walt Disney's streaming service Disney+ is rolling out its much-anticipated new ad-supported subscription plan for Disney+ in the U.S. as part of its bid to stem the loss and make its streaming business profitable after the services posted a hefty operating loss of more than $1 billion in the third quarter. It is also raising pricing for its bundled subscription plans with Hulu, ESPN+ and live TV. The U.S. Food and Drug Administration announced the intended availability of base powder to make around 6 million bottles of specialty formula from Mexico as part of its efforts to meet the nationwide supply shortage caused by Abbott Nutrition recall. Reckitt Nutrition/Mead Johnson Nutrition will send an initial shipment of 331 thousand pounds of base powder for PurAmino Hypoallergenic Formula. Shares of Deutsche Telekom AG were gaining more than 1 percent in the morning trading in Germany after the telecom major on Thursday raised its fiscal 2022 earnings outlook again, despite reporting lower profit in its second quarter. Adjusted EBITDA AL, a key earnings metric, increased, while adjusted EBITDA AL margin dropped.
Follow RTT